Immunologic analysis has greatly improved diagnostic accuracy in several clinically important areas, however, the ultimate goal of a lymphoma classifica tion based on immunophenotype has not been reached and may not be forth coming. In the evaluation of a patient suspected of having lymphoma, lympho cyte marker studies may be essential for a correct diagnosis, helpful but not essential, or entirely noncontributory, depending on the specific clinical setting and histological differential diagnosis. This review will cover the basic principles and technical aspects of marker studies, and will explore several problems in differential diagnosis to clarify the role of marker studies in determining patient management.
the care of individual patients. Both physicians caring for patients suspected of having lymphoma and pathologists faced with making the diagnosis on biopsy specimens must be aware of these issues, since often the manner in which the initial diagnostic biopsy is handled is crucial in determining whether or not a definite diagnosis will be made.
In the evaluation of a patient suspected of having lymphoma, lymphocyte market studies may be essential for a correct diagnosis, helpful but not essential, or entirely noncon tributory, depending on the specific clinical setting and histological differential diagnosis. This review will cover the basic principles and technical aspects of marker studies, and will explore several problems in differential diagnosis, to clarify the role of marker studies in determining patient management.
Principles of immunophenotyping Lymphocyte Differentiation
In many respects, lymphoid neoplasms resemble their normal counterparts, the T and B cells of the immune system. For this reason, some understanding of normal T and B cell differentiation is essential to an understanding of the lymphomas. At various stages of differentiation, lymphoid cells undergo changes in both morphology and surface antigen expression, which are characteristic for each stage. These features can be used to identify and characterize both normal and neoplastic lymphoid cells in tissue sections or cell suspensions. The constellation of antigens expressed at a given time by a cell is called its immunophenotype.
The nomenclature for both the morphologic stages and the surface antigens can be confusing, since different authorities use different morphologic terms for both nor mal and neoplastic lymphoid cells, and a variety of monoclonal antibodies with different names detect the same antigens. Morphologic terms used by four major lymphoma classifications are summarized in Table 1 . International workshops have recently de veloped a standardized nomenclature for many of the antigens detected by more than one monoclonal antibody.5 ,6 These clusters of differentiation (CD) are summarized in Table 2 . Not all of the antigens listed are currently useful in the diagnosis of lymphomas: some are not restricted to a particular cell type, while others cannot dis tinguish between neoplastic cells and infiltrating benign lymphocytes. In the discussion of practical application of marker studies, only those antibodies that are useful in clinically important differential diagnoses will be emphasized; the others are included because they are of interest for the understanding of lymphocyte differentiation and the subclassification of lymphomas in ways that do not yet have clinical relevance.
There are two distinct phases of development within both the T and B lymphoid cell lines: antigen-independent and antigen-dependent ( Figs. 1 and 2 ).7-9 Antigen-inde pendent proliferation and differentiation occur in the primary lymphoid organs (thymus Although the current understanding of both the immune system and the lymphomas is inadequate to permit this to be done in all the cases, the normal counterpart of many lymphomas can now be postulated with reasonable certainty.1,9
The term normal coun terpart does not mean cell of origin: it is possible to determine the stage of differentia tion of many lymphomas, but this does not mean that neoplastic transformation oc curred in a cell that had reached that stage. It may be that neoplastic transformation occurs in a primitive cell, and that the level of differentiation achieved by the tumor , depends on factors such as specific oncogene translocation . The immunological features of the lymphomas that can be recognized at present, arranged in order of their putative stage of differentiation, are summarized in Table 3 However, differences in classification schemes and antibody panels, as well as the small numbers of cases in any one study impair the usefulness of many of these observations.
Finally, it remains to be shown that subclassification by immunophenotype is as accurate or more accurate than morphology in predicting natural history and response to treat ment. This is a field whose potential has not been fully explored, and which will doubt less have more impact on diagnosis as more experience is gained.
Advances in the treatment of lymphomas will also influence the usefulness of marker studies. The current Working Formulation for non-Hodgkin's lymphomas23 subclassifies lymphomas according to their response to currently available treatment modalities. Clearly, if new modalities are discovered, this scheme may become irrele vant. If treatment with monoclonal antibodies becomes widespread, the immuno phenotype of a lymphoma will become its most important feature.
Conclusion
The correct diagnosis and subclassification of the lymphomas is of enormous clinical importance. These are tumors that affect individuals of all ages. They can be highly aggressive and fatal, or they can be indolent. Effective therapy exists for many of the more aggressive tumors, but the therapy is toxic and, occasionally, life-threaten ing, and should not be given unnecessarily. The treatment for lymphomas differs from that for nonlymphoid tumors in many cases, and also differs for the different subtypes of lymphoma.30 All these factors combine to make the diagnosis and subclassification of lymphomas much more important than it was only two decades ago.
The diagnosis of lymphoma on routinely processed histologic sections is one of the most difficult and poorly reproducible areas of histopathology. With the judicious application of immunophenotyping, diagnostic accuracy can be greatly improved. At present, immunophenotyping should be done in most cases of non-Hodgkin's lymphoma and in virtually all undifferentiated malignant tumors, to provide confirmation of the diagnosis.
The impact of immunophenotyping studies on diagnosis is threefold. First, in an individual case, a definite diagnosis can often be made which would have been impossible, incorrect, or only presumptive, if only routine histologic sections had been available. Second, the pathologist's "eye" is improved for future cases: if, knowing the results of the immunohistologic stains, routine sections are reexamined, the histologic criteria for making the diagnosis may be refined. Third, our understanding of the morphologic and clinical spectrum of the lymphomas is enhanced.
The contribution of marker studies to the diagnosis of lymphoma is well established.
Their potential contribution to subclassification has not been fully explored. 
